NCT01426100已完成3 期
A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of Telmisartan and S-Amlodipine(CKD-828) Versus Telmisartan Monotherapy in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 183
- 试验地点
- 18
- 主要终点
- Mean Sitting Diastolic Blood Pressure (MSDBP)
研究概览
简要总结
The aim of the present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (40/2.5mg and 40/5mg) compared with telmisartan monotherapy (80mg) in hypertensive patients inadequately controlled by telmisartan monotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age 18 years or older
- •diagnosis of essential hypertension and blood pressure not adequately controlled(inadequate control defined as seated diastolic blood pressure(DBP)>= 90mmHg if on existing antihypertensive treatment of seated DBP >= 100mmHg if treatment naive)
- •failure to respond to four weeks treatment with telmisartan 40mg(failure to respond defined as seated DBP >= 90mmHg)
- •willing and able to provide written informed consent
排除标准
- •mean seated DBP >= 120mmHg and/or mean seated SBP >= 200mmHg during run-in treatment or mean seated DBP >= 120mmHg and/or mean seated SBP >= 180mmHg at the randomization visit
- •known or suspected secondary hypertension(ex. aortic coarctation, Primary hyperaldosteronism, renal artery stenosis, pheochromocytoma)
- •has severe heart disease(Heart failure NYHA functional class 3, 4), unstable angina or myocardial infarction, arrhythmia within the past three months
- •has cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months
- •Type I Diabetes Mellitus, Type II Diabetes Mellitus with poor glucose control as defined by fasting glucosylated hemoglobin(HbA1c) > 8%
- •nown severe or malignant retinopathy
- •hepatic or renal dysfunction as defined by the following laboratory parameters: AST/ALT > UNL X 2, serum creatinine > UNL X 1.5
- •acute or chronic inflammatory status need to treatment
- •need to additional antihypertensive drugs during the study
- •need to concomitant medications known to affect blood pressure during the study
- •history of angioedema related to ACE inhibitors or Angiotensin II Receptor Blockers
- •known hypersensitivity related to either study drug
- •history of drug or alcohol dependency within 6 months
- •any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of investigational products(ex. gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bypass, active inflammatory bowel syndrome within 12 months prior to screening, gastric ulcers need to treatment, gastrointestinal/rectal bleeding, impaired pancreatic function such as pancreatitis, obstructions of the urinary tract or difficulty in voiding
- •administration of other study drugs within 30 days prior to randomization
- •premenopausal women(last menstruation < 1year) not using adequate contraception, pregnant or breast-feeding
- •history of malignancy including leukemia and lymphoma within the past 5 years
- •in investigator's judgment
研究组 & 干预措施
CKD-828 40/2.5mg
Experimental
干预措施: CKD-828 40/2.5mg (Drug)
CKD-828 40/5mg
Experimental
干预措施: CKD-828 40/5mg (Drug)
Telmisartan 80mg
Active Comparator
干预措施: Telmisartan 80mg (Drug)
结局指标
主要结局
Mean Sitting Diastolic Blood Pressure (MSDBP)
时间窗: After 8 weeks of treatment
次要结局
- Mean Sitting Diastolic Blood Pressure (MSDBP)(After 4 weeks of treatment)
- Mean Sitting Systolic Blood Pressure (MSSBP)(After 4 weeks and 8 weeks of treatment)
- Response rate(After 4 weeks and 8 weeks of treatment)
- Control rate(After 4 weeks and 8 weeks of treatment)
研究者
研究点 (18)
Loading locations...
相似试验
Unknown
3 期
Efficacy and Safety of TELMINUVO to Stage 2 HypertensionHypertensionNCT01983735Chong Kun Dang Pharmaceutical200
终止
2 期
Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular DegenerationAge-Related MaculopathyNCT01577381Pfizer10
已完成
2 期
Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic EndometriosisEndometriosisNCT01728454Repros Therapeutics Inc.60
进行中（未招募）
3 期
Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL PatientsSplenic Marginal Zone LymphomaNCT05735834International Extranodal Lymphoma Study Group (IELSG)122
进行中（未招募）
2 期
Tucatinib+Trastuzumab+Eribulin in HER2+ MBCPretreated Unresectable Locally Advanced or Metastatic HER2+ Breast CancerBreast CancerNCT05458674Criterium, Inc.17